Home Health & Hospice M&A in 2026: Why the Market Has Reset and What Buyers Want Now

This five-part series examines current trends in home health and hospice M&A as the sector enters 2026, including valuation discipline, compliance and clinical risk, the role of artificial intelligence, and how deal structure and preparation are affecting transaction outcomes.

Part 1 focuses on the current market environment and the factors driving buyer selectivity.

Key Takeaways

• The home health and hospice M&A market has moved away from peak-era valuation levels toward more disciplined underwriting focused on cash flow durability, compliance integrity, and operational performance.
• Deal activity increased in late 2025, but transactions are proceeding only for platforms that can demonstrate consistent documentation, sustainable growth, and operational control.
• Valuation is increasingly tied to verifiable performance, including compliance posture, revenue reliability, and technology infrastructure, rather than adjusted EBITDA narratives.

---

The Market Has Reopened on More Disciplined Terms

The home health and hospice sector is entering 2026 with renewed transaction activity. Capital remains available, and both private equity sponsors and strategic buyers continue to pursue platform and add-on acquisitions. Demand for home-based care is supported by long-term demographic trends and payor preferences.

At the same time, transaction conditions are more exacting than in prior years. Buyers are applying tighter underwriting standards, extending diligence timelines, and focusing on operational and clinical fundamentals. Transactions that might have advanced quickly several years ago are now subject to deeper review and more rigorous validation of performance.

From Peak Multiples to Disciplined Underwriting

Between 2019 and 2022, the home health and hospice M&A market experienced a period of high deal volume and aggressive pricing, with hospice assets in competitive processes commanding elevated valuation multiples.

That environment changed in 2023 and 2024. Rising interest rates and constrained credit markets reduced available leverage and increased the cost of capital. As a result, deal volume declined, and private equity sponsors became more selective in both platform investments and follow-on acquisitions.

Valuation methodologies also tightened. Buyers reduced tolerance for EBITDA add-backs, with adjustments moving from approximately 20% of EBITDA to a more constrained range of 12% to 15%. Greater emphasis is now placed on cash conversion, revenue consistency, and documentation that supports billing and reimbursement.

The prior environment, where pricing could be driven by growth projections or perceived synergies, has largely given way to a model grounded in demonstrated performance.

Deal Activity Is Recovering, but Selectively

The second half of 2025 brought increased transaction activity, particularly in hospice. Deal volume reached its highest level since 2021, supported by improving financing conditions and a significant amount of uninvested private equity capital.

Strategic buyers also remain active, especially those building multi-service platforms that combine hospice, home health, and related services.

Even with this increase in activity, buyers are not returning to prior pricing behavior. Transactions are advancing where targets can demonstrate operational discipline and predictable financial performance. Assets with inconsistent documentation, unclear growth drivers, or weak infrastructure are encountering pricing pressure or extended processes.

Well-managed hospice platforms with strong compliance records, diversified payor mix, and consistent growth continue to attract interest, with valuations in some cases ranging from 10x to 15x EBITDA.

Valuation Now Depends on Verifiable Performance

Buyers are placing increased weight on factors that can be validated through diligence and operating data. The following areas consistently influence transaction outcomes:

• Revenue durability and the sustainability of recent growth
• Documentation quality and support for eligibility and medical necessity
• Operational scalability, including the ability to grow without proportional increases in cost
• Technology infrastructure and integration across systems
• Depth and capability of management teams

Ownership of a particular electronic medical record system or presence in an attractive geography no longer drives pricing on its own. Buyers expect performance to be supported by consistent data and operational results.

Subsector Conditions Continue to Diverge

While the broader market reflects more disciplined underwriting, conditions vary across subsectors.

Hospice continues to attract strong buyer interest due to demographic demand and relatively stable reimbursement. Buyers are closely reviewing hospice cap exposure, length-of-stay patterns, and eligibility documentation to assess the reliability of revenue.

Home health remains an important component of integrated care platforms. Reimbursement pressure and administrative complexity require scale, operational discipline, and investment in systems capable of managing multiple payor requirements.

Personal care and home and community-based services (“HCBS”) are drawing attention as a means of diversifying revenue streams. Although these businesses often trade at lower multiples, they can contribute to platform value through scale and service line expansion.

The Gap Between High-Quality and Average Assets Is Increasing

Differences in operational quality are becoming more pronounced in transaction outcomes.

Organizations that demonstrate the following are more likely to achieve favorable valuations and transaction terms:

• Consistent and defensible documentation
• Established compliance infrastructure
• Reliable operational processes
• Data that supports reported performance

Providers that rely on fragmented systems, inconsistent practices, or aggressive financial adjustments are more likely to encounter extended diligence, pricing reductions, or difficulty completing a transaction.

How to Assess Timing

Transaction activity has increased, but buyers are advancing only those opportunities that withstand closer scrutiny. Organizations with consistent documentation, reliable data, and clear operational control are completing transactions on competitive terms.

Where those elements are less developed, processes tend to slow, with greater likelihood of pricing adjustments or additional diligence.

The practical takeaway is that timing alone is not determinative. Outcomes depend on whether a business can support its performance through diligence, which increasingly determines whether a transaction proceeds at expected value. For many organizations, this means that preparation — not market timing — is the primary driver of transaction success.

Implications for Buyers and Sellers

For buyers, the current environment offers opportunities to acquire strong platforms with greater pricing discipline, provided diligence confirms underlying performance.

For sellers, preparation is central to achieving expected outcomes. Documentation quality, compliance practices, and operational consistency are now primary considerations in valuation and deal execution.

Where the Market Is Headed

The current transaction environment reflects a longer-term recalibration rather than a temporary adjustment. Demographic demand and payor trends continue to support growth in home-based care, and consolidation across the sector is expected to continue.

Additionally, the threshold for what constitutes a strong acquisition target has increased. Compliance, operational execution, and technology capabilities are central to how buyers evaluate opportunities.

Assets that can demonstrate consistent performance and operational control are attracting capital, while others are facing increased scrutiny and pricing pressure. The following articles will examine how these dynamics affect compliance risk, diligence, valuation, the role of artificial intelligence, and deal structure in current transactions.

FAQ: Key Questions on Home Health and Hospice M&A

Why are home health and hospice M&A valuations changing in 2026?

Valuations are being driven by revenue durability, compliance support, and operational performance rather than adjusted EBITDA, leading to more disciplined pricing in healthcare transactions.

Do compliance issues still kill healthcare M&A deals?

Most healthcare transactions are not terminated for compliance issues, but they are frequently repriced through purchase price adjustments, escrows, or other structural protections.

What do buyers look for in home health and hospice M&A diligence?

Buyers focus on documentation quality, revenue sustainability, compliance infrastructure, and data consistency to confirm that reported performance can withstand audit and reimbursement scrutiny.

How can providers improve valuation in a home health or hospice transaction?

Providers can improve valuation by strengthening documentation practices, ensuring consistent operational data, and addressing compliance gaps before entering the market.